In-Person Access Only | 5.00 CE/CME Credits & MOC Points

Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $50 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com

Total Health, in partnership with the European Society for Medical Oncology (ESMO)—a global authority representing more than 50,000 oncology professionals— is proud to present a state-of-the-art program designed to deliver exclusive U.S.-based updates from the ESMO Breast Cancer Annual Congress.

This free, 1-day symposium for healthcare providers will spotlight the most important advances across the breast cancer continuum.

Conference Agenda
Saturday, May 16, 2026

\

7:30 AM
Coffee and Exhibits

8:00 AM
Program Chair Welcome

8:10 AM
Escalation vs de-escalation (HER2+, ER+)
Jairam Krishnamurthy, MD | Huntsman Cancer Institute

8:30 AM
Mechanisms of resistance to HER2-directed therapies
& strategies to overcome (bispecifics, switching, combination strategies)
Jairam Krishnamurthy, MD | Huntsman Cancer Institute

8:50 AM
MRD/ctDNA in early breast cancer
James Shortridge, DO | Utah Cancer Specialists

9:10 AM
Endocrine therapy & next-gen SERDs
Justin Call, MD | Utah Cancer Specialists

9:30 AM
Breakfast and Exhibits

9:45 AM
Non-CME Breakfast - Natera - Clinical utility of ctDNA testing for MRD with Signatera in breast cancer
Angel Rodriguez, MD | Natera

10:30 AM
CDK4/6 inhibitors across disease stages
Lee Schwartzberg, MD | Renown Health

10:50 AM
HER2-low and ultralow categories (ADC expansion)
Alexis LeVee, MD |University of California Los Angeles - Health Jonsson Comprehensive Cancer Center

11:10 AM
Survivorship and QOL
Daphne Stewart, MD | University of Southern California

11:30 AM
Emerging ADCs and novel targets in metastatic
disease
Hemali Batra-Sharma, MD | University of California San Francisco

11:50 AM
Lunch and Exhibits

12:05 PM
Non-CME Lunch - Pfizer Breast - Treatment Considerations for Patients With HR+/HER2- mBC
Anne O’Dea, MD | University of Kansas Cancer Center
Norma N. | Patient Ambassador

12:50 PM
Housekeeping and Survey

1:00 PM
Neoadjuvant IO in TNBC
Julie Williamson, MD | Huntsman Cancer Institute

1:20 PM
Biomarkers beyond ctDNA: TILs, immune signatures, tumor microenvironment in breast cancer
Mark Jesus Magbanua, PhD | University of California San Francisco

1:40 PM
Liquid biopsy–guided therapeutic escalation
(e.g. ESR1 mutation detection, early switch strategies)
Maria Hafez MD | St. Lukes University

2:00 PM
PI3K/AKT pathway inhibition: new agents, sequencing, combination strategies
Elena Shagisultanova, MD, PhD |Thomas Jefferson University

2:20 PM
Break and Exhibits

2:40 PM
AI / radiomics / imaging biomarkers in breast cancer
(predictive models, virtual biopsies)
Sarah Colonna, MD | Huntsman Cancer Institute

3:00 PM
Management of brain metastases in HER2+ and triple-negative breast cancer
Milana Dolezal, MD | Stanford Medicine

3:20 PM
Special populations: pregnancy-associated breast cancer, male breast cancer, BRCA mutation carriers
Sarah Colonna, MD | Huntsman Cancer Institute

3:40 PM
ADJOURN

All times are PST.

• Learning Objectives

  • Summarize recent advances in the diagnosis, staging, and treatment of breast cancer.  

  • Interpret emerging clinical trial data and its implications for current oncology practice. 

  • Enhance collaboration across the multidisciplinary cancer care team to improve patient outcomes. 

• Accreditation Information | 5.00 CME Credits & MOC Points

  In support of improving patient care, this activity has been planned and implemented by

  Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the

  Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council

  for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to

  provide continuing education for the healthcare team.

  Nurses

  Amedco LLC designates this activity for a maximum of 5.00 ANCC contact hours.

  Physicians

  Amedco LLC designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credits TM for physicians.

  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Pharmacists & Pharmacy Technicians

  Amedco LLC designates this activity for a maximum of 5.00 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Enduring video content for watching at your leisure

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program